Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Kiminori Kimura, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06144086CT.gov A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) | — | Completed | — | — | — |
NCT03620474CT.gov Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cirrhosis Of Liver
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Foscenvivint (this asset) | Kiminori Kimura, MD | P2 | BB · 69 |
| Veruprevir | AbbVie | P3 | A |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | General Hospital of Shenyang Military Region | P4 | BBB |
| Tolvaptan | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Cholyl-Lysl-Fluorescein | Norgine | P3 | BBB |
| Ribavirin | Peking University People's Hospital | P4 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BBB |
| Dasabuvir | AbbVie | P3 | BBB |
| Elbasvir | The HIV Netherlands Australia Thailand Research Collaboration | P4 | BBB |
+42 more in the Cirrhosis Of Liver cohort
Other indications for Foscenvivint
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 53 |
| Hepatitis C Virus Infection | — | P1/2 | CCC · 52 |
| Colorectal Adenocarcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Foscenvivint in Cirrhosis Of Liver. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/foscenvivint-cirrhosis-of-liver
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →